Asimov and Emergent sign two cell-line campaigns: CHO Edge to build high-titer research banks for two Ebola antibodies
Asimov and Emergent BioSolutions announced a cell-line development partnership covering two full campaigns, running from vector design and synthesis through production and shipment of a high-titer research cell bank, for two monoclonal antibodies targeting Ebola. Emergent aims to obtain high-titer cell lines using Asimov's CHO Edge System, which combines a GS knock-out CHO host, a hyperactive transposase, a genetic parts library and Kernel, Asimov's AI-driven genetic design software. The work sits at the cell-line development stage, and the companies describe an intent to accelerate candidate antibody development without reporting titers or antibody results.